Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. (Q36543189)
Jump to navigation
Jump to search
scientific article published on June 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. |
scientific article published on June 2006 |
Statements
Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma (English)
Kesava Reddy